You are here

Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Boston, Massachusetts, 02115 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Gastrointestinal Stromal Tumors
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histopathologically proven diagnosis of malignant GIST that was not amenable to
standard therapy.

- Failed prior treatment with imatinib mesylate, defined either by progression of
disease (according to Response Evaluation Criterion in Solid Tumors (RECIST) or World
Health Organization (WHO) criteria), or by significant toxicity during treatment with
imatinib mesylate that precluded further treatment. Intolerance to prior imatinib
mesylate therapy was defined as follows:

- Life-threatening adverse events (ie, Grade 4) at any dose (attempt to dose reduce or
rechallenge not required) or Unacceptable toxicity induced by a moderate dose (eg, 400
mg/day), specifically, Grade 2 toxicity that was unacceptable to the patient (such as
nausea) that persisted despite standard countermeasures

- Evidence of unidimensionally measurable disease.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Previous treatment on a SU011248 clinical trial.

- Diagnosis of any second malignancy within the last 3 years, except basal cell
carcinoma, squamous cell skin cancer, or in situ carcinoma, that had been adequately
treated with no evidence of recurrent disease for 12 months.

- History of or known brain metastases, spinal cord compression, or carcinomatous
meningitis, or new evidence of brain or leptomeningeal disease.

- Any of the following within the 12 months prior to starting the study treatment:
myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
graft, congestive heart failure, cerebrovascular accident or transient ischemic
attack, or pulmonary embolism.

- Ongoing cardiac dysrhythmias of grade 2, atrial fibrillation of any grade, or QTc
interval >450 msec for males or >470 msec for females.

- Hypertension that could not be controlled by medications (>150/100 mm/Hg despite
optimal medical therapy).

NCT00137449
Pfizer
Completed
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Gastrointestinal Stromal Tumors
NCT01396148
All Genders
6+
Years
Multiple Sites
Gastrointestinal Stromal Tumors
NCT00137449
All Genders
18+
Years
Multiple Sites
Gastrointestinal Stromal Tumors
NCT00457743
All Genders
20+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now